QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

EU CTA marks second regulatory clearance for Phase 1 ANQUR clinical trial of QRL-201 in ALS ANQUR is first-ever clinical trial to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients QurAlis recently announced first patient dosed in Canada; enrollment completed in Cohort…